Raltitrexed (Tomudex):: an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity

被引：62
|
作者：
Köhne, CH
Thuss-Patience, P
Friedrich, M
Daniel, PT
Kretzschmar, A
Benter, T
Bauer, B
Dietz, R
Dörken, B
机构：
[1] Humboldt Univ, Med Fak Charite, Virchow Klinikum,Robert Rossle Klin, Dept Haematol Oncol & Tumor Immunol, D-13125 Berlin, Germany
[2] Humboldt Univ, Med Fak Charite, Virchow Klinikum,Franz Volhard Klin, Dept Clin & Mol Cardiol, D-13125 Berlin, Germany
来源：
BRITISH JOURNAL OF CANCER | 1998年 / 77卷 / 06期
关键词：
5-fluorouracil; cardiotoxicity; raltitrexed; colorectal neoplasms;
D O I：
10.1038/bjc.1998.160
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Two patients with proven 5-fluorouracil (5-FU)-associated cardiotoxicity were treated with the specific thymidylate synthase inhibitor raltitrexed safely, without evidence of cardiotoxicity. Raltitrexed might be an alternative for patients with advanced colorectal cancer and 5-FU-associated cardiotoxicity. 5-FU cardiotoxicity is not due to the antineoplastic mechanisms via thymidilate synthase.
引用
收藏
页码：973 / 977
页数：5
相关论文
共 50 条
  • [1] Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity
    C-H Köhne
    P Thuss-Patience
    M Friedrich
    PT Daniel
    A Kretzschmar
    T Benter
    B Bauer
    R Dietz
    B Dörken
    British Journal of Cancer, 1998, 77 : 973 - 977
  • [2] Raltitrexed (Tomudex®):: An alternative choice in patients intolerant to 5-fluorouracil
    Kempin, S
    Gutierrez, J
    Wilson, E
    Lowery, C
    Diasio, R
    CANCER INVESTIGATION, 2002, 20 (7-8) : 992 - 995
  • [3] 'Tomudex' (raltitrexed) plus 5-fluorouracil: A promising option for the treatment of patients with metastatic colorectal cancer
    Schwartz, GK
    Bertino, J
    Kemeny, N
    Saltz, L
    Kelsen, DK
    Tong, W
    Barazzuol, J
    Lowery, C
    Smith, M
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S74 - S74
  • [4] An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer
    Groener, MGH
    van Ineveld, BM
    Byttebier, G
    van Hout, BA
    Rutten, FFH
    ANTI-CANCER DRUGS, 1999, 10 (03) : 283 - 288
  • [5] Cardiac outcomes of raltitrexed in the treatment of colorectal cancer patients with 5-fluorouracil (5-FU) cardiotoxicity
    Firouzbakht, Aryan
    Renouf, Daniel John
    Chen, Leo
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
    Nicolas Tsavaris
    Christos Kosmas
    Maria Vadiaka
    Christos Koufos
    BMC Cancer, 2
  • [7] Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
    Tsavaris, N
    Kosmas, C
    Vadiaka, M
    Koufos, C
    BMC CANCER, 2002, 2 (1)
  • [8] Raltitrexed (Tomudex™) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer:: Preliminary results from phase I clinical trials
    Schwartz, GK
    Harstrick, A
    Barón, MG
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S9 - S13
  • [9] Final results of a randomised trial comparing 'Tomudex'(R) (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
    Cunningham, D
    Zalcberg, JR
    Rath, U
    Oliver, I
    vanCutsem, E
    Svensson, C
    Seitz, JF
    Harper, P
    Kerr, D
    PerezManga, G
    ANNALS OF ONCOLOGY, 1996, 7 (09) : 961 - 965
  • [10] The use of raltitrexed (Tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia
    Nutting, C
    Folkes, A
    CLINICAL ONCOLOGY, 1999, 11 (01) : 66 - 66
12345